Description
Humana Press Oral Pharmacotherapy For Male Sexual Dysfunction A Guide To Clinical Management by Gregory A. Broderick
For the generation that reached sexual maturity in the 1960s, the "pill" became synonymous with sexual freedom and started a sexual revolution. For women it meant freedom from the fear of pregnancy, and for men enhanced sexual opportunity. The new era of the pill has nothing to do with fertility, but everything to do with sex. The first orally effective prescr- tion drug for treating erectile dysfunction (ED) was marketed in 1998. (R) Sildenafil (Viagra ) has rejuvenated the aging male veterans of the sexual revolution, forever changed the science of sexual medicine, and tra- formed society's perspective on aging and sex. This class of drugs, known as oral phosphodiesterase inhibitors (PDE-type 5), is highly effective in the treatment of ED. Since its introduction there has been a much greater awa- ness of ED, its comorbidities, and its effects on the quality of life. In 1997, while preparing to address the Endocrine Society on the occasion of the 92nd American Urological Association meeting, I first looked at the p- clinical studies of sildenafil. I thought "this will change everything" and it clearly has-changing practice patterns in sexual medicine, and the at- tudes of patients, potential patients, and their partners. Two new PDE-type (R) (R) 5 inhibitors, tadalafil (Cialis ) and vardenafil (Levitra ), were first approved by the European Committee for Proprietary Medicinal Products and subsequently by the Food and Drug Administration in 2003 and 2004.show more Physiology and Pharmacology of Erectile DysfunctionRafael Carrion, Derek Bochinski, Nadeem Rahman, and Tom F. LueEpidemiology of Erectile DysfunctionJonathan D. Schiff and John P. MulhallPharmacology of Phosphodiesterase InhibitorsErwin BischoffSildenafil Citrate, the Classical PDE5 Inhibitor: A Five-Year Review of its Efficacy and Safety in the Arena of Erectile DysfunctionHarin Padma-NathanTadalafil: Clinical Trials ExperienceCulley C. Carson, IIIVardenafil: Clinical Trials ExperienceAjay NehraErectile Dysfunction Assessment and Management in Primary Care PracticeLouis Kuritzky and Martin MinerWhen to Refer the Patient With Erectile Dysfunction to a SpecialistIra D. SharlipErectile Dysfunction: Assessing Risk and Managing the Cardiac PatientThorsten Reffelmann and Robert A. KlonerIs Diabetic Erectile Dysfunction More Difficult to Treat?Pierre Theuma and Vivian A. FonsecaDepression and Antidepressant-Associated Erectile DysfunctionRaymond C. RosenIntracavernous, Transurethral, and Topical Therapies for Erectile Dysfunction in the Era of Oral Pharmacotherapy: Salvaging First-Line Therapy Failures With Combination TherapiesHans-Martin A. Fritsche, Mustafa F. Usta, and Wayne J. G. HellstromAndrogen Deficiency of the Aging Male: Enhancing Erectile Response to Oral PharmacotherapyAlvaro Morales and Jeremy P. W. HeatonCentral Activation of Erection and Clinical ExperienceJeremy P. W. Heaton, Alvaro Morales, and Michael A. AdamsSustaining the Cure: Oral Pharmacotherapy Failures Salvag With Vacuum Devices and Penile ImplantsRonald W. LewisPrevention and Treatment of Erectile Dysfunction Utilizing Lifestyle Changes and Dietary Supplements: What Works and What is Worthless?Mark A. MoyadPharmacological Strategies in the Management of Rapid EjaculationChris G. McMahonSexual Dysfunction After Radical Prostatectomy and the Use of PDE-5 InhibitorsAndrew McCulloughFemale Sexual Dysfunction: Is There a Magic Pill?Ridwan Shabsigh, Anne R. Davis, Aristotelis G. Anastasiadis, Nawras Makhsida, and Grace YanIndex